Evidence map›Paper›PMID 40183043›Full record

ArticlePeerJ2025

Performance comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in detecting

Peng Lu, Haitao Yang, Fang Ge, Kai Wu, Yilin Lian, Xiaoyan Ding, Jingjing Pan, Hui Ding, Wei Lu, Qiao Liu and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peng Lu *Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Haitao Yang *Department of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Fang GeCentral Hospital, Jiangsu Prison Administration, Changzhou, China.
Kai WuCentral Hospital, Jiangsu Prison Administration, Changzhou, China.
Yilin LianSchool of Public Health, Southeast University, Nanjing, China.
Xiaoyan DingDepartment of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Jingjing PanDepartment of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Hui DingDepartment of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Wei LuDepartment of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Qiao LiuDepartment of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Limei ZhuDepartment of Chronic Communicable Disease, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: No direct comparative study assessing QuantiFERON-TB Gold In-Tube (QFT-GIT) and QuantiFERON-TB Gold Plus (QFT-Plus) for Methods: Simultaneous QFT-GIT and QFT-Plus tests were conducted on PLHIV in a prison hospital. Positivity and negativity results from both assays were compared, and their diagnostic agreement was assessed. Results: A total of 232 PLHIV individuals were included in this study. Among them, 57 patients (24.6%) and 56 patients (24.1%) were diagnosed with Conclusions: The diagnostic performance of QFT-GIT and QFT-Plus for

Indexed as

HIV InfectionsInterferon-gamma Release TestsMycobacterium tuberculosisTuberculosisAdultChinaFemaleHumansInterferon-gammaMaleMiddle AgedSensitivity and SpecificityTuberculin TestInterferon-gammaHIVMycobacterium tuberculosis infectionPreventive treatmentQFT-GITQFT-Plus

Identifiers

PMID40183043
PMCPMC11967438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.